PMID- 29029824
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210527
IS  - 2173-5808 (Electronic)
IS  - 2173-5808 (Linking)
VI  - 35
IP  - 3
DP  - 2020 Apr
TI  - Increased cerebrospinal fluid levels of cytokines monocyte chemoattractant 
      protein-1 (MCP-1) and macrophage inflammatory protein-1beta (MIP-1beta) in patients 
      with amyotrophic lateral sclerosis.
PG  - 165-169
LID - S0213-4853(17)30280-3 [pii]
LID - 10.1016/j.nrl.2017.07.020 [doi]
AB  - INTRODUCTION: Neuroinflammation has recently been described in amyotrophic 
      lateral sclerosis (ALS). However, the precise role of such proinflammatory 
      cytokines as monocyte chemoattractant protein-1 (MCP-1) and macrophage 
      inflammatory protein-1beta (MIP-1beta) in ALS has not yet been determined. In this 
      study, we determined cerebrospinal fluid (CSF) MCP-1 and MIP-1beta levels and 
      assessed their association with the duration and severity of ALS. METHODS: 
      Concentrations of MCP-1 and MIP-1beta were determined in the CSF of 77 patients 
      diagnosed with ALS and 13 controls. Cytokine levels were analysed in relation to 
      ALS duration (<12months vs. >12months) and severity (<30points vs. >30points on 
      the ALS Functional Rating Scale administered at hospital admission). RESULTS: 
      Higher CSF MIP-1beta (10.68pg/mL vs. 4.69pg/mL, P<.0001) and MCP-1 (234.89pg/mL vs. 
      160.95pg/mL, P=.011) levels were found in the 77 patients with ALS compared to 
      controls. There were no differences in levels of either cytokine in relation to 
      disease duration or severity. However, we did observe a significant positive 
      correlation between MIP-1beta and MCP-1 in patients with ALS. CONCLUSIONS: The 
      increase in MIP-1beta and MCP-1 levels suggests that these cytokines may have a 
      synergistic effect on ALS pathogenesis. However, in our cohort, no association 
      was found with either the duration or the clinical severity of the disease.
CI  - Copyright (c) 2017 Sociedad Espanola de Neurologia. Publicado por Elsevier Espana, 
      S.L.U. All rights reserved.
FAU - Martinez, H R
AU  - Martinez HR
AD  - Instituto de Neurologia y Neurocirugia, Centro Medico Zambrano Hellion, 
      Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico; Terapia 
      Celular, Centro de Innovacion y Transferencia en Salud (CITES), Escuela Nacional 
      de Medicina, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico; Servicio de 
      Neurologia, Hospital Universitario Universidad Autonoma de Nuevo Leon (UANL), 
      Monterrey, Nuevo Leon, Mexico. Electronic address: 
      dr.hectormartinez@medicos.tecsalud.mx.
FAU - Escamilla-Ocanas, C E
AU  - Escamilla-Ocanas CE
AD  - Instituto de Neurologia y Neurocirugia, Centro Medico Zambrano Hellion, 
      Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico; Terapia 
      Celular, Centro de Innovacion y Transferencia en Salud (CITES), Escuela Nacional 
      de Medicina, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico.
FAU - Camara-Lemarroy, C R
AU  - Camara-Lemarroy CR
AD  - Servicio de Neurologia, Hospital Universitario Universidad Autonoma de Nuevo Leon 
      (UANL), Monterrey, Nuevo Leon, Mexico.
FAU - Gonzalez-Garza, M T
AU  - Gonzalez-Garza MT
AD  - Terapia Celular, Centro de Innovacion y Transferencia en Salud (CITES), Escuela 
      Nacional de Medicina, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico.
FAU - Moreno-Cuevas, J
AU  - Moreno-Cuevas J
AD  - Terapia Celular, Centro de Innovacion y Transferencia en Salud (CITES), Escuela 
      Nacional de Medicina, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico.
FAU - Garcia Sarreon, M A
AU  - Garcia Sarreon MA
AD  - Servicio de Neurologia, Hospital Universitario Universidad Autonoma de Nuevo Leon 
      (UANL), Monterrey, Nuevo Leon, Mexico.
LA  - eng
LA  - spa
PT  - Journal Article
TT  - Incremento de las citoquinas proteina quimiotactica de monocitos-1 (MCP-1) y 
      proteina inflamatoria macrofagica-1beta (MIP-1beta) en liquido cefalorraquideo de 
      pacientes con esclerosis lateral amiotrofica.
DEP - 20171011
PL  - Spain
TA  - Neurologia (Engl Ed)
JT  - Neurologia
JID - 101778590
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL4)
RN  - 0 (Peptide Fragments)
RN  - 0 (monocyte chemoattractant protein 1 (66-77))
SB  - IM
MH  - Adult
MH  - Amyotrophic Lateral Sclerosis/*cerebrospinal fluid
MH  - Chemokine CCL2/*cerebrospinal fluid
MH  - Chemokine CCL4/*cerebrospinal fluid
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptide Fragments/*cerebrospinal fluid
OTO - NOTNLM
OT  - Amyotrophic lateral sclerosis (ELA)
OT  - Biomarcador
OT  - Biomarkers
OT  - Citoquinas
OT  - Cytokines
OT  - Esclerosis lateral amiotrofica (ELA)
OT  - MCP-1
OT  - MIP-1beta
OT  - Neuroinflamacion
OT  - Neuroinflammation
EDAT- 2017/10/17 06:00
MHDA- 2021/02/09 06:00
CRDT- 2017/10/15 06:00
PHST- 2017/01/05 00:00 [received]
PHST- 2017/04/19 00:00 [revised]
PHST- 2017/07/06 00:00 [accepted]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
PHST- 2017/10/15 06:00 [entrez]
AID - S0213-4853(17)30280-3 [pii]
AID - 10.1016/j.nrl.2017.07.020 [doi]
PST - ppublish
SO  - Neurologia (Engl Ed). 2020 Apr;35(3):165-169. doi: 10.1016/j.nrl.2017.07.020. 
      Epub 2017 Oct 11.